Akorn Target of Unusually High Options Trading (AKRX)

Akorn, Inc. (NASDAQ:AKRX) saw unusually large options trading on Thursday. Traders purchased 17,251 call options on the stock. This represents an increase of 1,245% compared to the typical volume of 1,283 call options.

Akorn stock opened at $5.59 on Friday. Akorn has a 1 year low of $4.82 and a 1 year high of $33.63. The company has a current ratio of 3.47, a quick ratio of 2.46 and a debt-to-equity ratio of 1.26.

Akorn (NASDAQ:AKRX) last issued its quarterly earnings data on Tuesday, November 6th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.07 by ($0.17). Akorn had a negative net margin of 34.69% and a negative return on equity of 14.97%. The business had revenue of $165.63 million during the quarter, compared to analyst estimates of $185.36 million. As a group, analysts expect that Akorn will post -0.13 EPS for the current year.

Several equities analysts have recently issued reports on the company. BidaskClub lowered Akorn from a “strong-buy” rating to a “buy” rating in a research report on Friday. Zacks Investment Research lowered Akorn from a “hold” rating to a “sell” rating in a research report on Tuesday, November 27th. Piper Jaffray Companies set a $9.00 target price on Akorn and gave the stock a “buy” rating in a research report on Tuesday, November 27th. Royal Bank of Canada set a $9.00 target price on Akorn and gave the stock a “hold” rating in a research report on Wednesday, November 7th. Finally, Craig Hallum upgraded Akorn from a “hold” rating to a “buy” rating in a research report on Thursday, October 4th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company’s stock. Akorn presently has a consensus rating of “Hold” and an average price target of $14.67.

Several institutional investors and hedge funds have recently modified their holdings of AKRX. Riverhead Capital Management LLC acquired a new position in shares of Akorn in the 2nd quarter valued at approximately $100,000. Tower Research Capital LLC TRC grew its position in shares of Akorn by 672.9% in the 3rd quarter. Tower Research Capital LLC TRC now owns 10,280 shares of the company’s stock valued at $134,000 after purchasing an additional 8,950 shares during the period. Baird Financial Group Inc. acquired a new position in shares of Akorn in the 3rd quarter valued at approximately $135,000. Brown Advisory Inc. acquired a new position in shares of Akorn in the 3rd quarter valued at approximately $139,000. Finally, Meadow Creek Investment Management LLC acquired a new position in shares of Akorn in the 2nd quarter valued at approximately $157,000. Institutional investors and hedge funds own 65.00% of the company’s stock.

WARNING: “Akorn Target of Unusually High Options Trading (AKRX)” was first reported by WKRB News and is owned by of WKRB News. If you are accessing this article on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The original version of this article can be viewed at https://www.wkrb13.com/2018/12/07/akorn-target-of-unusually-high-options-trading-akrx.html.

About Akorn

Akorn, Inc, a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health.

Further Reading: Do You Need a Fiduciary?

Receive News & Ratings for Akorn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply